These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 33397747)

  • 21. Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines.
    So MK; Jeong TD; Lim W; Moon BI; Paik NS; Kim SC; Huh J
    Breast Cancer; 2019 Jul; 26(4):510-519. PubMed ID: 30725392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of proactive high-throughput functional assay data on BRCA1 variant interpretation in 3684 patients with breast or ovarian cancer.
    Kim HK; Lee EJ; Lee YJ; Kim J; Kim Y; Kim K; Lee SW; Chang S; Lee YJ; Lee JW; Lee W; Chun S; Son BH; Jung KH; Kim YM; Min WK; Ahn SH
    J Hum Genet; 2020 Mar; 65(3):209-220. PubMed ID: 31907386
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Classification of 101 BRCA1 and BRCA2 variants of uncertain significance by cosegregation study: A powerful approach.
    Caputo SM; Golmard L; Léone M; Damiola F; Guillaud-Bataille M; Revillion F; Rouleau E; Derive N; Buisson A; Basset N; Schwartz M; Vilquin P; Garrec C; Privat M; Gay-Bellile M; Abadie C; Abidallah K; Airaud F; Allary AS; Barouk-Simonet E; Belotti M; Benigni C; Benusiglio PR; Berthemin C; Berthet P; Bertrand O; Bézieau S; Bidart M; Bignon YJ; Birot AM; Blanluet M; Bloucard A; Bombled J; Bonadona V; Bonnet F; Bonnet-Dupeyron MN; Boulaire M; Boulouard F; Bouras A; Bourdon V; Brahimi A; Brayotel F; Bressac de Paillerets B; Bronnec N; Bubien V; Buecher B; Cabaret O; Carriere J; Chiesa J; Chieze-Valéro S; Cohen C; Cohen-Haguenauer O; Colas C; Collonge-Rame MA; Conoy AL; Coulet F; Coupier I; Crivelli L; Cusin V; De Pauw A; Dehainault C; Delhomelle H; Delnatte C; Demontety S; Denizeau P; Devulder P; Dreyfus H; d'Enghein CD; Dupré A; Durlach A; Dussart S; Fajac A; Fekairi S; Fert-Ferrer S; Fiévet A; Fouillet R; Mouret-Fourme E; Gauthier-Villars M; Gesta P; Giraud S; Gladieff L; Goldbarg V; Goussot V; Guibert V; Guillerm E; Guy C; Hardouin A; Heude C; Houdayer C; Ingster O; Jacquot-Sawka C; Jones N; Krieger S; Lacoste S; Lallaoui H; Larbre H; Laugé A; Le Guyadec G; Le Mentec M; Lecerf C; Le Gall J; Legendre B; Legrand C; Legros A; Lejeune S; Lidereau R; Lignon N; Limacher JM; Doriane Livon ; Lizard S; Longy M; Lortholary A; Macquere P; Mailliez A; Malsa S; Margot H; Mari V; Maugard C; Meira C; Menjard J; Molière D; Moncoutier V; Moretta-Serra J; Muller E; Nevière Z; Nguyen Minh Tuan TV; Noguchi T; Noguès C; Oca F; Popovici C; Prieur F; Raad S; Rey JM; Ricou A; Salle L; Saule C; Sevenet N; Simaga F; Sobol H; Suybeng V; Tennevet I; Tenreiro H; Tinat J; Toulas C; Turbiez I; Uhrhammer N; Vande Perre P; Vaur D; Venat L; Viellard N; Villy MC; Warcoin M; Yvard A; Zattara H; Caron O; Lasset C; Remenieras A; Boutry-Kryza N; Castéra L; Stoppa-Lyonnet D
    Am J Hum Genet; 2021 Oct; 108(10):1907-1923. PubMed ID: 34597585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.
    Kurian AW; Ward KC; Hamilton AS; Deapen DM; Abrahamse P; Bondarenko I; Li Y; Hawley ST; Morrow M; Jagsi R; Katz SJ
    JAMA Oncol; 2018 Aug; 4(8):1066-1072. PubMed ID: 29801090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integration of functional assay data results provides strong evidence for classification of hundreds of BRCA1 variants of uncertain significance.
    Lyra PCM; Nepomuceno TC; de Souza MLM; Machado GF; Veloso MF; Henriques TB; Dos Santos DZ; Ribeiro IG; Ribeiro RS; Rangel LBA; Richardson M; Iversen ES; Goldgar D; Couch FJ; Carvalho MA; Monteiro ANA
    Genet Med; 2021 Feb; 23(2):306-315. PubMed ID: 33087888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation and Implementation of BRCA1/2 Variant Screening in Ovarian Tumor Tissue.
    de Jonge MM; Ruano D; van Eijk R; van der Stoep N; Nielsen M; Wijnen JT; Ter Haar NT; Baalbergen A; Bos MEMM; Kagie MJ; Vreeswijk MPG; Gaarenstroom KN; Kroep JR; Smit VTHBM; Bosse T; van Wezel T; van Asperen CJ
    J Mol Diagn; 2018 Sep; 20(5):600-611. PubMed ID: 29936257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide.
    Hirotsu Y; Schmidt-Edelkraut U; Nakagomi H; Sakamoto I; Hartenfeller M; Narang R; Soldatos TG; Kaduthanam S; Wang X; Hettich S; Brock S; Jackson DB; Omata M
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486089
    [No Abstract]   [Full Text] [Related]  

  • 28. The BRCA1 variant p.Ser36Tyr abrogates BRCA1 protein function and potentially confers a moderate risk of breast cancer.
    Christou CM; Hadjisavvas A; Kyratzi M; Flouri C; Neophytou I; Anastasiadou V; Loizidou MA; Kyriacou K
    PLoS One; 2014; 9(4):e93400. PubMed ID: 24695549
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation.
    Abkevich V; Zharkikh A; Deffenbaugh AM; Frank D; Chen Y; Shattuck D; Skolnick MH; Gutin A; Tavtigian SV
    J Med Genet; 2004 Jul; 41(7):492-507. PubMed ID: 15235020
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ClinVar at five years: Delivering on the promise.
    Landrum MJ; Kattman BL
    Hum Mutat; 2018 Nov; 39(11):1623-1630. PubMed ID: 30311387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and validation of a new algorithm for the reclassification of genetic variants identified in the BRCA1 and BRCA2 genes.
    Pruss D; Morris B; Hughes E; Eggington JM; Esterling L; Robinson BS; van Kan A; Fernandes PH; Roa BB; Gutin A; Wenstrup RJ; Bowles KR
    Breast Cancer Res Treat; 2014 Aug; 147(1):119-32. PubMed ID: 25085752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessing BRCA1 activity in DNA damage repair using human induced pluripotent stem cells as an approach to assist classification of BRCA1 variants of uncertain significance.
    Ozgencil M; Barwell J; Tischkowitz M; Izatt L; Kesterton I; Simpson M; Sharpe P; de Sepulveda P; Voisset E; Solomon E
    PLoS One; 2021; 16(12):e0260852. PubMed ID: 34855882
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Care in Specialized Centers and Data Sharing Increase Agreement in Hypertrophic Cardiomyopathy Genetic Test Interpretation.
    Furqan A; Arscott P; Girolami F; Cirino AL; Michels M; Day SM; Olivotto I; Ho CY; Ashley E; Green EM; Caleshu C;
    Circ Cardiovasc Genet; 2017 Oct; 10(5):. PubMed ID: 28986452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Post-mortem testing; germline BRCA1/2 variant detection using archival FFPE non-tumor tissue. A new paradigm in genetic counseling.
    Petersen AH; Aagaard MM; Nielsen HR; Steffensen KD; Waldstrøm M; Bojesen A
    Eur J Hum Genet; 2016 Aug; 24(8):1104-11. PubMed ID: 26733283
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incorporation of semi-quantitative analysis of splicing alterations for the clinical interpretation of variants in BRCA1 and BRCA2 genes.
    Montalban G; Bonache S; Moles-Fernández A; Gadea N; Tenés A; Torres-Esquius S; Carrasco E; Balmaña J; Diez O; Gutiérrez-Enríquez S
    Hum Mutat; 2019 Dec; 40(12):2296-2317. PubMed ID: 31343793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The challenge of comprehensive and consistent sequence variant interpretation between clinical laboratories.
    Pepin MG; Murray ML; Bailey S; Leistritz-Kessler D; Schwarze U; Byers PH
    Genet Med; 2016 Jan; 18(1):20-4. PubMed ID: 25834947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exceptions to the rule: case studies in the prediction of pathogenicity for genetic variants in hereditary cancer genes.
    Rosenthal ET; Bowles KR; Pruss D; van Kan A; Vail PJ; McElroy H; Wenstrup RJ
    Clin Genet; 2015 Dec; 88(6):533-41. PubMed ID: 25639900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combining Homologous Recombination and Phosphopeptide-binding Data to Predict the Impact of
    Petitalot A; Dardillac E; Jacquet E; Nhiri N; Guirouilh-Barbat J; Julien P; Bouazzaoui I; Bonte D; Feunteun J; Schnell JA; Lafitte P; Aude JC; Noguès C; Rouleau E; Lidereau R; Lopez BS; Zinn-Justin S; Caputo SM;
    Mol Cancer Res; 2019 Jan; 17(1):54-69. PubMed ID: 30257991
    [No Abstract]   [Full Text] [Related]  

  • 39. BRCA1/2 sequence variants of uncertain significance: a primer for providers to assist in discussions and in medical management.
    Lindor NM; Goldgar DE; Tavtigian SV; Plon SE; Couch FJ
    Oncologist; 2013; 18(5):518-24. PubMed ID: 23615697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variant Interpretation for Cancer (VIC): a computational tool for assessing clinical impacts of somatic variants.
    He MM; Li Q; Yan M; Cao H; Hu Y; He KY; Cao K; Li MM; Wang K
    Genome Med; 2019 Aug; 11(1):53. PubMed ID: 31443733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.